(Q43835717)

27 November 2017

title

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer (English)

1 reference

27 November 2017

1 reference

Konecny G

1

1 reference

27 November 2017

Fritz M

2

1 reference

27 November 2017

Untch M

3

1 reference

27 November 2017

Lebeau A

4

1 reference

27 November 2017

Felber M

5

1 reference

27 November 2017

Lude S

6

1 reference

27 November 2017

Beryt M

7

1 reference

27 November 2017

Hepp H

8

1 reference

27 November 2017

Slamon D

9

1 reference

27 November 2017

Pegram M

10

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Breast Cancer Research and Treatment

27 November 2017

published in

1 reference

27 November 2017

volume

69

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

53-63

1 reference

HER-2/neu as a predictive marker of response to breast cancer therapy

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012226006395

7 January 2021

Identifiers

DOI

10.1023/A:1012226006395

1 reference

Dimensions Publication ID

27 November 2017

1014260511

0 references

1 reference